Department of Breast Cancer Surgery, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China.
North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China.
Mol Med Rep. 2018 Mar;17(3):4639-4644. doi: 10.3892/mmr.2018.8427. Epub 2018 Jan 12.
Breast cancer tissues and adjacent tissues were collected from 32 patients who were treated in The Third Hospital of Chengde City. Reverse transcription‑quantitative polymerase chain reaction results demonstrated that, compared with the adjacent tissues, interleukin (IL)‑23/IL‑23 receptor (R) gene expression levels were notably higher in breast cancer tissues. Furthermore, IL‑23 and IL‑23R expression levels were positively correlated with patients' tumor size, TNM stage and metastasis. Recombinant human (rh) IL‑23 (10 ng/ml) was used for the stimulation of the MCF‑7 cell line. Effects of rh IL‑23 (10 ng/ml) on cell proliferation was detected after MCF‑7 cells were incubated with rh IL‑23 for 48 h. Whether pre‑treatment with polyclonal antibody (PAb) IL‑23p19, a neutralizing antibody specific for IL‑23, may influence the effects of IL‑23 on cell behavior was also investigated. Cell proliferation assay and cell apoptosis assay were evaluated using MTT assay and flow cytometry assay, respectively. Results suggested that PAb IL‑23p19 reduced IL-23-induced cell proliferation whereas induced IL‑23 inhibited cell apoptosis. Western blot analysis was performed for the detection of molecules that may be responsible for the aforementioned changes. Results indicated that PAb IL‑23p19 treatment reduced IL‑23‑induced upregulation of B‑cell lymphoma‑2 protein expression and activation of the janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. The present results suggested that IL‑23 may be a potential prognosis marker and target for the treatment of breast cancer patients.
从在承德市第三医院接受治疗的 32 名患者中收集乳腺癌组织和相邻组织。逆转录-定量聚合酶链反应结果表明，与相邻组织相比，乳腺癌组织中白细胞介素（IL）-23/IL-23 受体（R）基因表达水平明显更高。此外，IL-23 和 IL-23R 的表达水平与患者的肿瘤大小、TNM 分期和转移呈正相关。用重组人（rh）IL-23（10ng/ml）刺激 MCF-7 细胞系。在 MCF-7 细胞用 rhIL-23 孵育 48h 后，检测 rhIL-23（10ng/ml）对细胞增殖的影响。还研究了多克隆抗体（PAb）IL-23p19（针对 IL-23 的中和抗体）预处理是否可能影响 IL-23 对细胞行为的影响。使用 MTT 测定法和流式细胞术分别评估细胞增殖测定和细胞凋亡测定。结果表明，PAb IL-23p19 减少了 IL-23 诱导的细胞增殖，而诱导的 IL-23 抑制了细胞凋亡。进行 Western blot 分析以检测可能负责上述变化的分子。结果表明，PAb IL-23p19 处理减少了 IL-23 诱导的 B 细胞淋巴瘤-2 蛋白表达上调和 Janus 激酶 2/信号转导和转录激活因子 3 信号通路的激活。这些结果表明，IL-23 可能是治疗乳腺癌患者的潜在预后标志物和靶标。
